p53 Protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast

European Journal of Cancer Part A

Volumn 33, Issue 1, 1997, Pages 39-44

  Rudas, M ^a   Neumayer, R ^a   Gnant, M F X ^b   Mittelbock M ^b   Jakesz, R ^b   Reiner, A ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

c erbB 2; CLIS; DCIS; growth fraction; minimal invasive cancer; p53; steroid hormone receptors

Indexed keywords

ONCOPROTEIN; PROTEIN P53; STEROID RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CARCINOMA IN SITU; CELL PROLIFERATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; ONCOGENE C ERB; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CELL DIVISION; FEMALE; HUMANS; NEOPLASM PROTEINS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031021137     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00368-1     Document Type: Article

References (32)

1. 1. Patchefsky AS, Schwartz GF, Finkelstein SD, et al. Heterogeneity of intraductal carcinoma of the breast. Cancer 1989, 63, 731-741.
2. 2. Posner MC, Wolmark N. Non-invasive breast carcinoma. Breast Cancer Res Treat 1992, 21, 155-164.
3. 3. Lagios MD. Heterogeneity of ductal carcinoma in situ of the breast. J Cell Biochem Suppl 1993, 17G, 49-52.
4. 4. Recht A, van Dongen JA, Fentiman IS, et al. Third meeting of the DCIS working party of the EORTC (Fondazione Cini, Isola S. Giorgio, Venezia, 28 February 1994) - Conference report. Eur J Cancer 1994, 30A, 1895-1901.
5. 5. Holland R, Peterse JL, Millis RR, et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagnostic Pathol 1994, 11, 167-180.
6. 6. Tavassoli FA. Pathology of the Breast. Norwalk, Connecticut, Appleton & Lange, 1992, 298-300.
7. 7. Key G, Becker MHG, Bron B, et al. New Ki-67 equivalent murine monoclonal antibodies (MIB 1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the KI-67 epitope. Lab Invest 1993, 68, 629-636.
8. 8. Banks L, Matlashewski G, Crawford L. Isolation of human p53 specific antibodies and their use in the study of human p53 expression. Eur J Biochem 1986, 159, 529-534.
9. 9. Corbett IP, Henry JA, Angus B, et al. NCL-CB11, a new monoclonal antibody recognizing the internal domain of the c-erbB-2 oncogene protein effective for use on formalin-fixed, paraffin-embedded tissue. J Pathol 1990, 161, 15-25.
10. 10. Davidoff AM, Kerns B-JM, Iglehart JD, et al. Maintenance of p53 alterations throughout breast cancer progression. Cancer Res 1991, 51, 2605-2610.
11. 11. Thor AD, Moore DH, Edgerton SM, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis of breast cancers. J Natl Cancer Inst 1992, 84, 845-855.
12. 12. Poller DN, Roberts EC, Bell JA, et al. p53 expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein. Hum Pathol 1993, 24, 463-468.
13. 13. Barbareschi M, Leonardi E, Mauri FA, et al. p53 and c-erbB-2 expression in breast carcinomas: an immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. Am J Clin Pathol 1992, 98, 408-418.
14. 14. Davidoff AM, Herndon JE, Glover NS, et al. Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery 1991, 110, 259-264.
15. 15. Cattoretti G, Rilke F, Andreola S, et al. p53 expression in breast cancer. Int J Cancer 1988, 41, 178-183.
16. 16. Martinazzi M, Crivelli F, Zampatti C, et al. Relationship between p53 expression and other prognostic factors in human breast carcinoma: an immunohistochemical study. Am J Clin Pathol 1993, 100, 213-217.
17. 17. Ramachandra S, Machin L, Ashley S, et al. Immunohistochemical distribution of c-erbB-2 in in situ breast carcinoma - a detailed morphological analysis. J Pathol 1990, 161, 7-14.
18. 18. Somerville JE, Clarke LA, Biggart JD. c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma. J Clin Pathol 1992, 45, 16-20.
19. 19. Bartkova J, Barnes DM, Millis RR, et al. Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ. Hum Pathol 1990, 21, 1164-1167.
20. 20. Barnes DM, Meyer JS, Gonzalez JG, et al. Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ. Breast Cancer Res Treat 1991, 18, 11-17.
21. 21. Allred DC, Clark GM, Molina R, et al. Overexpression of HER-2/neu and is relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 1992, 23, 974-979.
22. 22. Meyer JS. Cell kinetics of histologic variants of in situ breast carcinoma. Breast Cancer Res Treat 1986, 7, 171-180.
23. 23. Rudas M, Gnant MFX, Mittlböck M, et al. Thymidine labeling index and Ki-67 growth fraction in breast cancer: comparison and correlation with prognosis. Breast Cancer Res Treat 1994, 32, 165-175.
24. 24. Pallis L, Wilking N, Cedermark B, et al. Receptors for estrogen and progesterone in breast carcinoma in situ. Anticancer Res 1992, 12, 2113-2116.
25. 25. Bur ME, Zimarovsky MJ, Schnitt SJ, et al. Estrogen receptor immunohistochemistry in carcinoma in situ of the breast. Cancer 1992, 69, 1174-1181.
26. 26. Giri DD, Dundas SAC, Nottingham JF, et al. Oestrogen receptors in benign epithelial lesions and intraductal carcinomas of the breast: an immunohistochemical study. Histopathology 1989, 15, 575-584.
27. 27. Poller DN, Snead DRJ, Roberts EC, et al. Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein. Br J Cancer 1993, 68, 156-161.
28. 28. Reiner A, Reiner G, Spona J, et al. Histopathologic characterization of human breast cancer in correlation with estrogen receptor status: a comparison of immunocytochemical and biochemical analysis. Cancer 1988, 61, 1149-1154.
29. 29. Ji H, Lipponen P, Aaltomaa S, et al. c-erbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer. Anticancer Res 1993, 13, 1147-1152.
30. 30. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957, 11, 359-377.
31. 31. le Doussal V, Tubiana-Hulin M, Friedman S, et al. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR): an improved score modification based on a multivariate analysis of 1262 invasive ductal breast cancers. Cancer 1989, 64, 1914-1921.
32. 32. Schumacher M, Schmoor C, Sauerbrei W, et al. The prognostic effect of histological tumor grade in node-negative breast cancer patients. Breast Cancer Res Treat 1993, 25, 235-245.